Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) had a rough 2011. If the pre-market trading indications manage to last throughout the day, then it appears that Teva could be off to a great start in 2012. The company just announced that it will have a new Chief Executive Officer. Whether you look at Teva for its generic gains or its branded products, this may matter. The company’s current CEO will retire in May and will be replaced by Jeremy Levin upon retirement. Teva was well above $50 throughout much of early 2011 and ended up going under $40.00 before recovering. Shares closed out at $40.36 on Friday and the stock is indicated up 3.6% at $41.82 so far this Tuesday morning to start of 2012.
JON C. OGG
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
